|
Global X Marijuana Life Sciences Index ETF (HMMJ)
|
As of October 31, 2024
|
|
(Sector Equity)
|
|
Underlying Index
|
North American Medical Marijuana Index
|
Inception Return
(4/4/2017)
|
-12.69 %
|
|
Day High/Low
|
$10.25 / $10.17
|
|
YTD Return
|
12.27 %
|
|
52Week High/Low
|
$11.91 / $8.59
|
|
|
|
|
|
NAVPS
(12/2/2024)
|
$10.21
|
|
Change
|
$0.03 / 0.25 %
|
Open / Close
(12/2/2024)
|
$10.17
/
$10.19
|
|
|
|
Management Fee
|
0.75 %
|
|
Traded Volume
|
10,623
|
|
Assets ($mil)
|
-
|
|
Rank (1Yr)
|
97/189
|
|
Std Dev (3Yr)
|
50.70 %
|
|
Beta (3Yr)
|
1.46
|
|
Volatility Ranking (3Yr)
|
10/10
|
|
RRSP Eligibility
|
Yes
|
|
Open to Invest
|
Open
|
|
Annual Dividend
|
$0.27
|
|
Annual Yield
|
2.64 %
|
|
|
Objective
The investment objective of the ETF is to seek to replicate, to the extent possible, the performance of the North American Marijuana Index, net of expenses. The North American Marijuana Index is designed to provide exposure to the performance of a basket of North American publicly listed companies with significant business activities in the marijuana industry.
|
Fund Manager
Global X Investments Canada Inc.
Portfolio Manager
Global X Investments Canada Inc.
Sub-Advisor
Data not available
|
|
Asset Allocation
(As of October 31, 2024)
|
Sector Allocation
(As of October 31, 2024)
|
Geographic Allocation
(As of October 31, 2024)
|
Top 10 Holdings
| Name | Asset | Sector | Geographic | Percent |
| Innovative Industrial Properties Inc | US Equity | Real Estate | United States | 18.41% |
| Jazz Pharmaceuticals PLC | International Equity | Healthcare | European Union | 12.76% |
| Scotts Miracle-Gro Co | US Equity | Basic Materials | United States | 11.30% |
| Tilray Brands Inc | US Equity | Healthcare | United States | 9.59% |
| Chart Industries Inc | US Equity | Industrial Goods | United States | 9.07% |
| Cronos Group Inc | Canadian Equity | Healthcare | Canada | 8.38% |
| SNDL Inc | Canadian Equity | Consumer Goods | Canada | 5.53% |
| Corbus Pharmaceuticals Holdings Inc | US Equity | Healthcare | United States | 4.74% |
| Canopy Growth Corp | Canadian Equity | Healthcare | Canada | 3.76% |
| SKYE BIOSCIENCE INC | US Equity | Other | United States | 3.15% |
Performance Data
(As of October 31, 2024)
|
|
Return (%)
|
Annualized Return (%)
|
|
Return
|
1
Mth
|
3
Mth
|
6
Mth
|
YTD
|
1
Yr
|
3
Yr
|
5
Yr
|
10
Yr
|
|
Fund
|
-1.13
|
-7.99
|
-11.57
|
12.27
|
25.31
|
-27.91
|
-21.51
|
-
|
|
Benchmark
|
0.85
|
5.30
|
12.95
|
18.24
|
32.06
|
8.05
|
11.33
|
8.41
|
|
Quartile Ranking
|
3
|
4
|
4
|
3
|
3
|
4
|
4
|
-
|
|
Calendar Return (%)
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
2014
|
|
Fund
|
-18.82
|
-52.54
|
-18.99
|
-1.28
|
-33.82
|
-19.82
|
-
|
-
|
-
|
-
|
|
Benchmark
|
11.75
|
-5.84
|
25.09
|
5.60
|
22.88
|
-8.89
|
9.10
|
21.08
|
-8.32
|
10.55
|
|
Quartile Ranking
|
4
|
4
|
4
|
4
|
4
|
4
|
-
|
-
|
-
|
-
|